MODEL VERDICT
ProMIS Neurosciences, Inc. (PMN)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Feb 28, 2026 | MODERATE | 0.61 | $23.51 | CURRENT | -54.0% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| Industry Median P/E 48 industry peers | $59.96 | +155.0% | 15% | A | Peer Data |
| Earnings Yield 47 industry peers | $73.00 | +210.5% | 2% | B | Data |
| Weighted Output Blended model output | $59.06 | +151.2% | 100% | 55 | SIGNIFICANTLY UNDERVALUED |
| EPS Growth ↓ | P/E Multiple → | 5× | 7× | 9× (Current) | 11× | 13× |
|---|---|---|---|---|---|
| Bear Case (4%) | $14 | $20 | $26 | $31 | $37 |
| Conservative (7%) | $15 | $21 | $26 | $32 | $38 |
| Base Case (10.0%) | $15 | $21 | $27 | $33 | $39 |
| Bull Case (14%) | $16 | $22 | $28 | $34 | $41 |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 30.13 | 5.36 | 1.52 | 96.54 | 40.97 |
| P/B Ratio | 27.37 | 5.34 | 1.52 | 84.83 | 36.09 |
| P/S Ratio | 46115.72 | 21348.52 | 4691.62 | 137074.21 | 61393.09 |
Based on our peer multiples analysis with 4 valuation metrics, the model estimates PMN's fair value at $59.06 vs the current price of $23.51, implying +151.2% upside potential. Model verdict: Significantly Undervalued. Confidence: 55/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $59.06 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $12.01 (P10) to $122.84 (P90), with a median of $63.51.
PMN's current P/E of 8.5x compares to the industry median of 21.8x (48 peers in the group). This represents a -60.8% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
2 analysts cover PMN with a consensus rating of Buy. The consensus price target is $18.00 (range: $18.00 — $18.00), implying -23.4% upside from the current price. Grade breakdown: Strong Buy (0), Buy (2), Hold (0), Sell (0), Strong Sell (0).
The model confidence score is 55/100, based on: data completeness (6), peer quality (25), historical depth (16), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for PMN.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.